PMC reviews insights from the 41st JP Morgan Healthcare conference, focusing on some of the new treatments and technologies to watch out for in the pharma industry this year – and highlighting challenges to progress.
Fears of a shortage of medical devices have led the European Commission (EC) to adopt a proposal to extend the transition period to new rules under the Medical Devices Regulation. The proposal was made at the EPSCO Council meeting on 9 December 2022 by EU health ministers.
A free webinar on the M11 Guideline has been organised by the International Council for Harmonisation (ICH) M11 Expert Working Group (EWG). The Guideline is an initiative to promote greater harmonisation across international clinical trial protocols. The webinar takes place on 26 January 2023 at 10am-12pm EST (3-5pm GMT).
The UK BioIndustry Association (BIA) appears to have won a reprieve on proposed cuts to SME R&D tax credits, via a letter from Chancellor Jeremy Hunt. The policy was introduced in the Government’s Autumn Statement in November 2022, due to take effect in April 2023.
The European Medicines Agency (EMA) has issued a reminder that from 31 January 2023 clinical trial sponsors must use the Clinical Trials Information System (CTIS) for initial trial applications.
The Office of Health Economics (OHE) launched a biennial competition in early 2022 to answer the question ‘How can policymakers design a system to generate fair prices that balances access and innovation throughout the lifecycle of medicines?’ Join the live online ceremony on 24 January 2023.
The European Medicines Agency (EMA) and European Centre for Disease Prevention and Control (ECDC) held the first meeting of the Immunisation and Vaccine Monitoring Advisory Board (IVMAB) of the Vaccine Monitoring Platform (VMP) in early December. Via the VMP they will coordinate and oversee EU-funded, independent post-authorisation studies on vaccines use, safety and effectiveness in EU countries.
On 13 December 2022 the UK government announced a programme of funding for genomic research, including £105 million for diagnosis of rare genetic diseases in newborns, plus funding to improve the accuracy and speed of cancer diagnosis, and support for new technologies across the health and care system.
A deal valued at $27.8 billion has been struck between Amgen and Horizon Therapeutics, wherein Amgen will buy the orphan drug manufacturer.
In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).
